Literature DB >> 7438128

Update results of vindesine as a single agent in the therapy of advanced malignant melanoma.

S Retsas, I Peat, R Ashford, M Coe, J Maher, A Drury, I W Hanham, R H Phillips, K A Newton, G Westbury.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7438128     DOI： 10.1016/s0305-7372(80)80014-4

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  5 in total

1.  Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines.

Authors:  A Photiou; M N Sheikh; D Bafaloukos; S Retsas
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  Systemic therapy of malignant melanoma.

Authors:  J Hansson
Journal:  Med Oncol       Date:  1997-06       Impact factor: 3.064

3.  A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.

Authors:  Christopher W Lee; Karl Bélanger; Sanjay C Rao; Teresa M Petrella; Richard G Tozer; Lori Wood; Kerry J Savage; Elizabeth A Eisenhauer; Timothy W Synold; Nancy Wainman; Lesley Seymour
Journal:  Invest New Drugs       Date:  2007-10-26       Impact factor: 3.850

4.  Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study.

Authors:  U Ringborg; C M Rudenstam; J Hansson; L Hafström; B Stenstam; H Strander
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

5.  Vindesine: phase II evaluation in colon cancer and description of its platelet stimulating activity.

Authors:  R Pazdur; A H Rossof; G Chandra; P D Bonomi; R E Slayton; J Wolter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.